Differential regulation of angiotensin converting enzyme 2 and nuclear factor-κB by angiotensin II receptor subtypes in type 2 diabetic kidney

Biochimie

Volumn 118, Issue , 2015, Pages 71-81

  Pandey, Anuradha ^a   Goru, Santosh Kumar ^a   Kadakol, Almesh ^a   Malek, Vajir ^a   Gaikwad, Anil Bhanudas ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

ACE2; AT1 receptor; AT2 receptor; NF kB signalling pathway; Oxidative stress

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALBUMIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR; CHOLESTEROL; CREATININE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; NITROGEN; TELMISARTAN; TRANSCRIPTION FACTOR NRF2; TRIACYLGLYCEROL; UREA; ANGIOTENSIN 1 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY HYPERTROPHY; KIDNEY MASS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; RECEPTOR BLOCKING; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; VASOCONSTRICTION; ANIMAL; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PATHOLOGY; PHYSIOLOGY; RAT; WISTAR RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; NF-KAPPA B; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; SIGNAL TRANSDUCTION;

EID: 84940041804     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2015.08.005     Document Type: Article

References (62)

1. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, and D.R. Matthews Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
2. H.-J. Anders, and M. Ryu Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis Kidney Int. 80 2011 915 925
3. A. Fukuda, L.T. Wickman, M.P. Venkatareddy, Y. Sato, M.A. Chowdhury, S.Q. Wang, K.A. Shedden, R.C. Dysko, J.E. Wiggins, and R.C. Wiggins Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease Kidney Int. 81 2012 40 55
4. J. Mori, V.B. Patel, T. Ramprasath, O.A. Alrob, J. DesAulniers, J.W. Scholey, G.D. Lopaschuk, and G.Y. Oudit Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity Am. J. Physiol. Ren. Physiol. 306 2014 F812 F821
5. J.M. Turner, C. Bauer, M.K. Abramowitz, M.L. Melamed, and T.H. Hostetter Treatment of chronic kidney disease Kidney Int. 81 2011 351 362
6. L.C. Matavelli, J. Huang, and H.M. Siragy Angiotensin AT2 receptor stimulation inhibits early renal inflammation in renovascular hypertension Hypertension 57 2011 308 313
7. J.L. Zhuo AT2 receptors in cortical collecting ducts: a novel role in mediating ROMK-like K+ channel responses to high dietary K+? Am. J. Physiol.-Ren. Physiol. 307 2014 F1134 F1135
8. M. Alique, E. Sánchez-López, S. Rayego-Mateos, J. Egido, A. Ortiz, and M. Ruiz-Ortega Angiotensin II, via angiotensin receptor type 1/nuclear factor-κB activation, causes a synergistic effect on interleukin-1-β-induced inflammatory responses in cultured mesangial cells J. Renin Angiotensin Aldosterone Syst. 16 2015 23 32
9. M. Ruiz-Ortega, M. Ruperez, O. Lorenzo, V. Esteban, J. Blanco, S. Mezzano, and J. Egido Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney Kidney Int. 62 2002 S12 S22
10. S. Mezzano, C. Aros, A. Droguett, M.E. Burgos, L. Ardiles, C. Flores, H. Schneider, M. Ruiz-Ortega, and J. Egido NF-κB activation and overexpression of regulated genes in human diabetic nephropathy Nephrol. Dial. Transpl. 19 2004 2505 2512
11. J.W. Gordon, J.A. Shaw, and L.A. Kirshenbaum Multiple facets of NF-κB in the heart to be or not to NF-κB Circ. Res. 108 2011 1122 1132
12. M. Ruiz Ortega, O. Lorenzo, M. Rupérez, Y. Suzuki, and J. Egido Angiotensin II activates nuclear transcription factor-κB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice Nephrol. Dial. Transpl. 16 2001 27 33
13. M. Ruiz-Ortega, Ó. Lorenzo, M. Rupérez, J. Blanco, and J. Egido Systemic infusion of angiotensin II into normal rats activates nuclear factor-κB and AP-1 in the kidney: role of AT1 and AT2 receptors Am. J. Pathol. 158 2001 1743 1756
14. G. Wolf, U. Wenzel, K.D. Burns, R.C. Harris, R.A. Stahl, and F. Thaiss Angiotensin II activates nuclear transcription factor-kB through AT1 and AT2 receptors Kidney Int. 61 2002 1986 1995
15. G. Wolf, F.N. Ziyadeh, F. Thaiss, J. Tomaszewski, R.J. Caron, U. Wenzel, G. Zahner, U. Helmchen, and R. Stahl Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor J. Clin. Invest. 100 1997 1047 1057
16. M. Ruiz-Ortega, M. Rupérez, V. Esteban, J. Rodriguez-Vita, E. Sanchez-López, and J. Egido Modulation of angiotensin II effects, a potential novel approach to inflammatory and immune diseases Curr. Med. Chem. Anti Inflamm. Anti Allergy Agents 2 2003 379 394
17. V. Esteban, O. Lorenzo, M. Rupérez, Y. Suzuki, S. Mezzano, J. Blanco, M. Kretzler, T. Sugaya, J. Egido, and M. Ruiz-Ortega Angiotensin II, via AT1 and AT2 Receptors and NF-κB Pathway, Regulates the Inflammatory Response in Unilateral Ureteral Obstruction J. Am. Soc. Nephrol. 15 2004 1514 1529
18. M.P. Ocaranza, and J.E. Jalil Protective role of the ACE2/Ang-(1-9) axis in cardiovascular remodeling Int. J. Hypertens. 2012 2012 1 12
19. S.M. Bindom, and E. Lazartigues The sweeter side of ACE2: physiological evidence for a role in diabetes Mol. Cell. Endocrinol. 302 2009 193 202
20. Q. Ali, Y. Wu, and T. Hussain Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats Kidney Int. 84 2013 931 939
21. S. Sriramula, J.P. Cardinale, E. Lazartigues, and J. Francis ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension Cardiovasc Res. 92 2011 401 408
22. M.J. Soler, M. Ye, J. Wysocki, J. William, J. Lloveras, and D. Batlle Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan Am. J. Physiol. Ren. Physiol. 296 2009 F398 F405
23. T.D. Obr, and E. Lazartigues Angiotensin-II receptors regulate ACE2 expression in the brain FASEB J. 20 2006 LB35 42
24. R. Nadarajah, R. Milagres, M. Dilauro, A. Gutsol, F. Xiao, J. Zimpelmann, C. Kennedy, J. Wysocki, D. Batlle, and K.D. Burns Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice Kidney Int. 82 2012 292 303
25. C.X. Liu, Q. Hu, Y. Wang, W. Zhang, Z.Y. Ma, J.B. Feng, R. Wang, X.P. Wang, B. Dong, F. Gao, M.X. Zhang, and Y. Zhang Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition Mol. Med. 17 2011 59 69
26. H.-Y. Jin, B. Song, G.Y. Oudit, S.T. Davidge, H.-M. Yu, Y.-Y. Jiang, P.-J. Gao, D.-L. Zhu, G. Ning, and Z. Kassiri ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production PloS One 7 2012 e38502 38508
27. A. Simoes e Silva, K. Silveira, A. Ferreira, and M. Teixeira ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis Brit J. Pharmacol. 169 2013 477 492
28. Y. Meng, C.-H. Yu, W. Li, T. Li, W. Luo, S. Huang, P.-S. Wu, S.-X. Cai, and X. Li Angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-κB pathway Am. J. Respir. Cell Mol. Biol. 50 2013 723 736
29. M.A. Nobrega, S. Fleming, R.J. Roman, M. Shiozawa, N. Schlick, J. Lazar, and H.J. Jacob Initial characterization of a rat model of diabetic nephropathy Diabetes 53 2004 735 742
30. R.S. Danda, N.M. Habiba, H. Rincon-Choles, B.K. Bhandari, J.L. Barnes, H.E. Abboud, and P.E. Pergola Kidney involvement in a nongenetic rat model of type 2 diabetes Kidney Int. 68 2005 2562 2571
31. A. Gaikwad, J. Gupta, and K. Tikoo Epigenetic changes and alteration of Fbn1 and Col3A1 gene expression under hyperglycaemic and hyperinsulinaemic conditions Biochem. J. 432 2010 333 341
32. A. Kadakol, V. Malek, S.K. Goru, A. Pandey, and A.B. Gaikwad Esculetin reverses histone H2A/H2B ubiquitination, H3 dimethylation, acetylation and phosphorylation in preventing type 2 diabetic cardiomyopathy J. Funct. Foods 17 2015 127 136
33. A.B. Gaikwad, B. Viswanad, and P. Ramarao PPARγ agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance Pharmacol. Res. 55 2007 400 407
34. G. Umschweif, S. Liraz-Zaltsman, D. Shabashov, A. Alexandrovich, V. Trembovler, M. Horowitz, and E. Shohami Angiotensin Receptor Type 2 Activation Induces Neuroprotection and Neurogenesis After Traumatic Brain Injury Neurotherapeutics 11 2014 665 678
35. T. Ohmura, I. Tsunenari, R. Seidler, M. Chachin, T. Hayashi, A. Konomi, T. Matsumaru, T. Sumida, N. Hayashi, and Y. Horie Renoprotective effects of telmisartan on renal injury in obese Zucker rats Acta Diabetol. 49 2012 15 24
36. Y. Ayele, K. Urga, and E. Engidawork Evaluation of in vivo antihypertensive and in vitro vasodepressor activities of the leaf extract of Syzygium guineense (Willd) DC Phytother. Res. 24 2010 1457 1462
37. A. Kadakol, V. Malek, S.K. Goru, A. Pandey, S. Bagal, and A.B. Gaikwad Esculetin attenuates alterations in Ang II and acetylcholine mediated vascular reactivity associated with hyperinsulinemia and hyperglycemia Biochem. Biophys. Res. Commun. 461 2015 342 347
38. H. Ohkawa, N. Ohishi, and K. Yagi Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction Anal. Biochem. 95 1979 351 358
39. A.F. Boyne, and G.L. Ellman A methodology for analysis of tissue sulfhydryl components Anal. Biochem. 46 1972 639 653
40. V. Ninichuk, S. Clauss, O. Kulkarni, H. Schmid, S. Segerer, E. Radomska, D. Eulberg, K. Buchner, N. Selve, and S. Klussmann Late onset of CCl2 blockade with the Spiegelmer mNOX-E36-3′ PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice Am. J. Pathol. 172 2008 628 637
41. M. Tsuda, W. Zhang, G.X. Yang, K. Tsuneyama, Y. Ando, K. Kawata, O. Park, P.S. Leung, R.L. Coppel, and A.A. Ansari Deletion of interleukin (IL) 12p35 induces liver fibrosis in dominant negative TGFβ receptor type II mice Hepatology 57 2013 806 816
42. C.N. Bradford, D.R. Ely, and M.K. Raizada Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy Curr. Hypertens. Rep. 12 2010 212 219
43. K.O. Alsaad, and A.M. Herzenberg Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update J. Clin. Pathol. 60 2007 18 26
44. O.O. Erejuwa, S.A. Sulaiman, M.S. Ab Wahab, K.N. Sirajudeen, S. Salleh, and S. Gurtu Honey supplementation in spontaneously hypertensive rats elicits antihypertensive effect via amelioration of renal oxidative stress Oxid. Med. Cell. Longev. 2012 2012 1 14
45. M. Ruiz-Ortega, V. Esteban, Y. Suzuki, M. Ruperez, S. Mezzano, L. Ardiles, P. Justo, A. Ortiz, and J. Egido Renal expression of angiotensin type 2 (AT2) receptors during kidney damage Kidney Int. 64 2003 S21 S26
46. K. Taguchi, T. Matsumoto, K. Kamata, and T. Kobayashi Angiotensin II type 2 receptor-dependent increase in nitric oxide synthase activity in the endothelium of db/db mice is mediated via a MEK pathway Pharmacol. Res. 66 2012 41 50
47. J.H. Lee, S. Xia, and L. Ragolia Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats Am. Physiol. Soc. 295 2008 R144 R154
48. Q. Ali, R. Sabuhi, and T. Hussain High glucose up-regulates angiotensin II subtype 2 receptors via interferon regulatory factor-1 in proximal tubule epithelial cells Mol. Cell Biochem. 344 2010 65 71
49. C. Bregonzio, A. Seltzer, I. Armando, J. Pavel, and J. Saavedra Angiotensin II AT1 receptor blockade selectively enhances brain AT2 receptor expression, and abolishes the cold-restraint stress-induced increase in tyrosine hydroxylase mRNA in the locus coeruleus of spontaneously hypertensive rats Stress 11 2008 457 466
50. D.I.O. Melo, N.K. Mattocks, K. Xu, R. Griffiths, T.M. Coffman, and S.B. Gurley Loss of either renal or systemic ACE2 contributes to the hypertensive response to chronic angiotensin II Hypertension 60 2012 A225 A230
51. M.A. Ferguson, and S.S. Waikar Established and emerging markers of kidney function Clin. Chem. 58 2012 680 689
52. D.J. Leehey, A.K. Singh, N. Alavi, and R. Singh Role of angiotensin II in diabetic nephropathy Kidney Int. 58 2000 S93 S98
53. V. Koka, X.R. Huang, A.C. Chung, W. Wang, L.D. Truong, and H.Y. Lan Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway Am. J. Pathol. 172 2008 1174 1183
54. M. Ye, J. Wysocki, P. Naaz, M.R. Salabat, M.S. LaPointe, and D. Batlle Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 43 2004 1120 1125
55. M. Ye, J. Wysocki, J. William, M.J. Soler, I. Cokic, and D. Batlle Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes J. Am. Soc. Nephrol. 17 2006 3067 3075
56. C. Tikellis, K. Bialkowski, J. Pete, K. Sheehy, Q. Su, C. Johnston, M.E. Cooper, and M.C. Thomas ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes Diabetes 57 2008 1018 1025
57. J. Wysocki, M. Ye, M.J. Soler, S.B. Gurley, H.D. Xiao, K.E. Bernstein, T.M. Coffman, S. Chen, and D. Batlle ACE and ACE2 activity in diabetic mice Diabetes 55 2006 2132 2139
58. N.E. Clarke, N.D. Belyaev, D.W. Lambert, and A.J. Turner Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress Clin. Sci. 126 2014 507 516
59. A.P. Lakshmanan, K. Watanabe, R.A. Thandavarayan, F.R. Sari, M. Harima, V.V. Giridharan, V. Soetikno, M. Kodama, and Y. Aizawa Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action Free Radic. Res. 45 2011 575 584
60. X.Y. Tian, W.T. Wong, A. Xu, Z.Y. Chen, Y. Lu, L.M. Liu, V.W. Lee, C.W. Lau, X. Yao, and Y. Huang Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress Brit J. Pharmacol. 164 2011 598 606
61. E. Kansanen, S.M. Kuosmanen, H. Leinonen, and A.-L. Levonen The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer Redox Biol. 1 2013 45 49
62. A.L. Stefanson, and M. Bakovic Dietary regulation of Keap1/Nrf2/ARE pathway: focus on plant-derived compounds and trace minerals Nutrients 6 2014 3777 3801